Merck
CN

1271700

USP

氟康唑

United States Pharmacopeia (USP) Reference Standard

登录to View Organizational & Contract Pricing

Select a Size

Change View
别名:
2-(2,4-二氟苯基)-1,3-双(1H-1,2,4-三唑-1-基)丙-2-醇
Empirical Formula (Hill Notation):
C13H12F2N6O
CAS号:
分子量:
306.27
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API family

fluconazole

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

格式

neat

SMILES string

FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

InChI key

RFHAOTPXVQNOHP-UHFFFAOYSA-N

正在寻找类似产品? Visit 产品对比指南

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
Y0000557F8929Y0000558
Fluconazole United States Pharmacopeia (USP) Reference Standard

USP

1271700

氟康唑

Fluconazole European Pharmacopoeia (EP) Reference Standard

Y0000557

氟康唑

Fluconazole ≥98% (HPLC), powder

Sigma-Aldrich

F8929

氟康唑

Fluconazole for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000558

氟康唑

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

-

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

-

format

neat

API family

fluconazole

API family

fluconazole

API family

-

API family

fluconazole

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

生化/生理作用

氟康唑是一种抗真菌剂。是真菌细胞色素P-450甾醇C-14α-去甲基化的高选择性抑制剂。氟康唑是一种有效的CYP2C9抑制剂。氟康唑可干扰真菌麦角甾醇合成并下调金属硫蛋白基因。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

象形图

Exclamation markHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

其他客户在看

Slide 1 of 7

1 of 7

vibrant-m

Y0000573

氟康唑杂质B

Supelco

Supelco

PHR1900

氟康唑杂质A

Tinidazole United States Pharmacopeia (USP) Reference Standard

USP

1667520

替硝唑

Voriconazole United States Pharmacopeia (USP) Reference Standard

USP

1718008

伏立康唑

USP

USP

1171706

去乙酰地尔硫卓 盐酸盐

Ofloxacin United States Pharmacopeia (USP) Reference Standard

USP

1478108

氧氟沙星

Itraconazole United States Pharmacopeia (USP) Reference Standard

USP

1354251

伊曲康唑

Fluconazole
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(6), 1901-1901 (2020)
Fluconazole in Dextrose Injection
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1907-1907 (2018)
Fluconazole in Sodium Chloride Injection
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1909-1909 (2018)
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Kim C M van der Elst et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1527-1533 (2014-08-26)
Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. Although timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended. We conducted a retrospective study of critically ill children treated

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门